Fillable Heptavalent Botulism Antitoxin reporting forms - Epidemiology.
7 Nov 2011. Tender/contract/opportunity summary for: BOTULINUM ANTITOXIN HEPTAVALENT.
Heptavalent botulinum antitoxin (HBAT) replaces licensed bivalent botulinum antitoxin AB (BAT-AB) and investigational monovalent botulinum antitoxin E.
primates. the products were shown to neutralize each of the botulinum toxin serotypes in vitro; mice injected with a mixture of heptavalent antitoxin and a specific.

Botulism Antitoxin, Heptavalent, Bivalent, EDB Muscle, Paralysis.

Botulism antitoxin heptavalent regulatory update - BioCentury.com.
Cangene - Biodefense Products.
5 Jun 2006. HHS has awarded a contract to the Cangene Corporation in the amount of $362641105 for 200000 doses of Heptavalent Botulism Antitoxin.
25 Sep 2012. In addition to the equine-derived heptavalent botulinum antitoxin available from the CDC for use in non-infant botulism cases, a human-derived.
Botulism Antitoxin Heptavalent is an investigational product containing antibodies specific for the seven botulinum toxin types: A, B, C, D, E, F and G. Botulinum.
Published on Monday, January 21, 2013. Cangene Corp. (TSX:CNJ), Winnipeg, Manitoba Product: Botulism antitoxin heptavalent (BAT). 10 words displayed of.
17 Jun 2010. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin.
11 Jan 2013. Now FDA says a third product, Cangene's biologics licensing application (BLA) for botulism antitoxin heptavalent (A, B, C, D, E, F, G)-(Equine).

Botulinum antitoxin compositions and methods - Google.

Unbound MEDLINE : Investigational heptavalent botulinum antitoxin.

botulism antitoxin heptavalent

Cangene - Cangene's heptavalent botulism antitoxin delivered and.

botulism antitoxin heptavalent

Botulism Fact Sheet -- Center for Biosecurity of UPMC.

7 Nov 2011. Tender/contract/opportunity summary for: BOTULINUM ANTITOXIN HEPTAVALENT.
Heptavalent botulinum antitoxin (HBAT) replaces licensed bivalent botulinum antitoxin AB (BAT-AB) and investigational monovalent botulinum antitoxin E.